Are we treating to target?

Kannel, 1995, An update on coronary risk factors, Med. Clin. N. Am., 79, 951, 10.1016/S0025-7125(16)30016-5 Manninen, 1988, Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study, J. Am. Med. Assoc., 260, 641, 10.1001/jama.1988.03410050061031 Pedersen, 1998, Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S), Circulation, 97, 1453, 10.1161/01.CIR.97.15.1453 Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators, N Eng J Med, 335, 1001, 10.1056/NEJM199610033351401 Wood D, de Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K, members of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19(10):1434–1503. EUROASPIRE Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principle results. Eur Heart J 1997;18:1569–82. Campbell, 1998, Secondary prevention in coronary heart disease: baseline survey of provision in general practice, Br. Med. J., 316, 1430, 10.1136/bmj.316.7142.1430 Pearson, 2000, The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals, Arch Inc Med, 160, 459, 10.1001/archinte.160.4.459 National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994;89(3):1333–1445. Harnick, 1998, Effects of practice setting on quality of lipid-lowering management in patients with coronary artery disease, Am. J. Cardiol., 81, 1416, 10.1016/S0002-9149(98)00209-4 Unwin, 1998, Implications of applying widely accepted cholesterol screening and management guidelines to a British adult population: cross sectional study of cardiovascular disease and risk factors, Br. Med. J., 317, 1125, 10.1136/bmj.317.7166.1125 Hibble, 1998, Guidelines in general practice: the new Tower of Babel?, Br. Med. J., 317, 862, 10.1136/bmj.317.7162.862 Gandhi, 1995, Management of angina pectoris in general practice: a questionnaire survey of general practitioners, Br. J. Gen. Pract., 45, 11 Shepherd, 1997, International comparison of awareness and attitudes towards coronary risk factor reduction: the HELP study, J. Cardiovasc. Risk, 4, 373, 10.1097/00043798-199710000-00010 Grimshaw, 1993, Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations, Lancet, 342, 1317, 10.1016/0140-6736(93)92244-N Thomas, 1997, Improving care with nurse case managers: practical aspects of designing lipid clinics, Am. J. Cardiol., 80, 62H, 10.1016/S0002-9149(97)00823-0 Campbell, 1998, Secondary prevention clinics for coronary heart disease: randomised trial of effect on health, Br. Med. J., 316, 1434, 10.1136/bmj.316.7142.1434 Erhardt, 1999, Quality assurance of secondary prevention — a solution to better implementation of guidelines, Scand. Cardiovasc. J., 33, 3, 10.1080/14017439950141957 Bowker, 1996, A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (action on secondary prevention through intervention to reduce events), Heart, 75, 334, 10.1136/hrt.75.4.334